- Home
- NNOX vs ALLO Comparison
NNOX vs ALLO Comparison
Compare NNOX & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNOX
- ALLO
- Stock Information
- Founded
- NNOX 2011
- ALLO 2017
- Country
- NNOX Israel
- ALLO United States
- Employees
- NNOX N/A
- ALLO N/A
- Industry
- NNOX Medical Electronics
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NNOX Health Care
- ALLO Health Care
- Exchange
- NNOX Nasdaq
- ALLO Nasdaq
- Market Cap
- NNOX 248.7M
- ALLO 231.9M
- IPO Year
- NNOX 2020
- ALLO 2018
- Fundamental
- Price
- NNOX $3.87
- ALLO $1.13
- Analyst Decision
- NNOX Strong Buy
- ALLO Strong Buy
- Analyst Count
- NNOX 2
- ALLO 10
- Target Price
- NNOX $8.50
- ALLO $8.88
- AVG Volume (30 Days)
- NNOX 1.3M
- ALLO 4.8M
- Earning Date
- NNOX 08-12-2025
- ALLO 08-13-2025
- Dividend Yield
- NNOX N/A
- ALLO N/A
- EPS Growth
- NNOX N/A
- ALLO N/A
- EPS
- NNOX N/A
- ALLO N/A
- Revenue
- NNOX $11,886,000.00
- ALLO N/A
- Revenue This Year
- NNOX $24.12
- ALLO N/A
- Revenue Next Year
- NNOX $160.56
- ALLO $100.00
- P/E Ratio
- NNOX N/A
- ALLO N/A
- Revenue Growth
- NNOX 17.36
- ALLO N/A
- 52 Week Low
- NNOX $3.75
- ALLO $0.86
- 52 Week High
- NNOX $11.00
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- NNOX 30.71
- ALLO 47.01
- Support Level
- NNOX $3.89
- ALLO $1.13
- Resistance Level
- NNOX $4.16
- ALLO $1.27
- Average True Range (ATR)
- NNOX 0.19
- ALLO 0.08
- MACD
- NNOX -0.02
- ALLO 0.02
- Stochastic Oscillator
- NNOX 3.81
- ALLO 50.00
About NNOX NANO-X IMAGING LTD
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.